APA (7th ed.) Citation

E, C., P, P., O, D., C, T., G, M., C, A., . . . U, D. (2002). Slowly progressing type 1 diabetes: Persistence of islet cell autoantibodies is related to glibenclamide treatment. Autoimmunity, 35(7), 469. https://doi.org/10.1080/0891693021000050574

Chicago Style (17th ed.) Citation

E, Cabrera-Rode, et al. "Slowly Progressing Type 1 Diabetes: Persistence of Islet Cell Autoantibodies Is Related to Glibenclamide Treatment." Autoimmunity 35, no. 7 (2002): 469. https://doi.org/10.1080/0891693021000050574.

MLA (9th ed.) Citation

E, Cabrera-Rode, et al. "Slowly Progressing Type 1 Diabetes: Persistence of Islet Cell Autoantibodies Is Related to Glibenclamide Treatment." Autoimmunity, vol. 35, no. 7, 2002, p. 469, https://doi.org/10.1080/0891693021000050574.